We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.70 | 1.61% | 44.15 | 44.33 | 43.96 | 44.13 | 3,104,015 | 01:00:00 |
From May 2019 to May 2024
By Denise Roland
LONDON--GlaxoSmithKline PLC (GSK) said net profit fell in the first quarter due to a tough year-earlier comparison, which was boosted by proceeds from its three-way transaction with Novartis AG; taking out that effect, profit rose--partly due to cost savings from the same deal.
The U.K.-based pharmaceuticals company said net income for the three months ended March 31 was 282 million pounds ($410 million), a fraction of the GBP8.1 billion reported a year earlier.
Core net income, which strips out one-time gains and impairments, increased 15% to GBP959 million, from GBP834 million a year ago. Revenue rose 11% to GBP6.2 billion, up from GBP5.6 billion a year ago. Glaxo beat expectations on both fronts: analysts were expecting core net income of GBP894 million and revenue of GBP6 billion.
Write to Denise Roland at denise.roland@wsj.com
(END) Dow Jones Newswires
April 27, 2016 07:33 ET (11:33 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
